Patients with inflammatory bowel diseases (IBD) are estimated to be at 5 to 10 times greater risk for development of colorectal cancer, and accurate detection of dysplasia is key to the prevention of cancer morbidity and mortality, as well as to the reduction of unneeded surgical procedures. A new long-term surveillance study appearing online in the journal Clinical Gastroenterology and Hepatology concludes that chromoendoscopy is superior to the more typically used random biopsy or white-light colonoscopy in detecting these precancerous lesions. Chromoendoscopy is an inexpensive technique that uses stains during endoscopy to highlight mucosal abnormalities that could indicate colorectal cancer risk.
In the current study, data were analyzed from 68 patients with ulcerative colitis or Crohn’s disease. Researchers concluded that chromoendoscopy was more likely to detect the presence of dysplasia, and that a negative chromoendoscopy result accurately predicted that advanced dysplasia would not develop, thereby forestalling an unnecessary colon resection. Lead author James Marion, MD, Professor of Medicine at Icahn School of Medicine at Mount Sinai, observed “While there has been a growing consensus on the superiority of chromoendoscopy compared to other dysplasia surveillance methods over the last decade, these results are the first to demonstrate this superiority through long-term surveillance.”
Read more about IBD here.
A news story about the findings and recommendations may be read here.